daraxonrasib

all catalysts(1)

News(10)

• Opinion: STAT+: The NIH budget should be $100 billion per year
  “We should be strengthening our investment in the NIH, not dismantling it,” writes Reed Jobs.
  stat · 13d ago
• In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
  In his first interview after taking the reins of the FDA’s Oncology Center of Excellence, Angelo de Claro, M.D., is outlining a regulatory agenda that prioritizes organizational strength and contin…
  fiercebiotech · 23d ago
• A breakthrough pancreatic cancer drug won approval. They still struggle to access it
  When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.
  stat · 26d ago
• Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
  Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
  biopharma_dive · 1mo ago
• RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
  The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall re…
  biospace · 1mo ago
• STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
  The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter
  stat · 1mo ago
• RevMed could become ‘next oncology titan’ with Rasonque nod
  A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.
  biospace · 1mo ago
• Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
  Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
  biopharma_dive · 1mo ago
• RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
  The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.
  biospace · 1mo ago
• FDA approves Revolution Medicines' pancreatic cancer drug
  The FDA gave the green light to a highly anticipated pancreatic cancer treatment that has altered the prospects for patients facing the deadly disease. The agency on Wednesday approved Revolution M…
  endpoints · 1mo ago